111 related articles for article (PubMed ID: 18538948)
41. A novel approach with magnetic resonance imaging used for the detection of lung allograft rejection.
Kanno S; Lee PC; Dodd SJ; Williams M; Griffith BP; Ho C
J Thorac Cardiovasc Surg; 2000 Nov; 120(5):923-34. PubMed ID: 11044319
[TBL] [Abstract][Full Text] [Related]
42. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
43. In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: detection and monitoring at 3T.
Ittrich H; Lange C; Tögel F; Zander AR; Dahnke H; Westenfelder C; Adam G; Nolte-Ernsting C
J Magn Reson Imaging; 2007 Jun; 25(6):1179-91. PubMed ID: 17520738
[TBL] [Abstract][Full Text] [Related]
44. Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging.
Senéterre E; Weissleder R; Jaramillo D; Reimer P; Lee AS; Brady TJ; Wittenberg J
Radiology; 1991 May; 179(2):529-33. PubMed ID: 2014305
[TBL] [Abstract][Full Text] [Related]
45. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
McPhail LD; Chung YL; Madhu B; Clark S; Griffiths JR; Kelland LR; Robinson SP
Clin Cancer Res; 2005 May; 11(10):3705-13. PubMed ID: 15897567
[TBL] [Abstract][Full Text] [Related]
46. Fetal body volume at MR imaging to quantify total fetal lung volume: normal ranges.
Cannie MM; Jani JC; Van Kerkhove F; Meerschaert J; De Keyzer F; Lewi L; Deprest JA; Dymarkowski S
Radiology; 2008 Apr; 247(1):197-203. PubMed ID: 18258812
[TBL] [Abstract][Full Text] [Related]
47. In vivo detection of developing vessel occlusion in photothrombotic ischemic brain lesions in the rat by iron particle enhanced MRI.
Kleinschnitz C; Schütz A; Nölte I; Horn T; Frank M; Solymosi L; Stoll G; Bendszus M
J Cereb Blood Flow Metab; 2005 Nov; 25(11):1548-55. PubMed ID: 15917747
[TBL] [Abstract][Full Text] [Related]
48. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.
Robinson SP; McIntyre DJ; Checkley D; Tessier JJ; Howe FA; Griffiths JR; Ashton SE; Ryan AJ; Blakey DC; Waterton JC
Br J Cancer; 2003 May; 88(10):1592-7. PubMed ID: 12771928
[TBL] [Abstract][Full Text] [Related]
49. Quantification of renal perfusion using an intravascular contrast agent (part 1): results in a canine model.
Aumann S; Schoenberg SO; Just A; Briley-Saebo K; Bjørnerud A; Bock M; Brix G
Magn Reson Med; 2003 Feb; 49(2):276-87. PubMed ID: 12541248
[TBL] [Abstract][Full Text] [Related]
50. DMXAA: an antivascular agent with multiple host responses.
Baguley BC; Ching LM
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1503-11. PubMed ID: 12459378
[TBL] [Abstract][Full Text] [Related]
51. Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors.
Rodrigues LM; Howe FA; Griffiths JR; Robinson SP
J Magn Reson Imaging; 2004 Apr; 19(4):482-8. PubMed ID: 15065173
[TBL] [Abstract][Full Text] [Related]
52. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics.
Lutz AM; Weishaupt D; Persohn E; Goepfert K; Froehlich J; Sasse B; Gottschalk J; Marincek B; Kaim AH
Radiology; 2005 Mar; 234(3):765-75. PubMed ID: 15665219
[TBL] [Abstract][Full Text] [Related]
53. [Iron-oxide-enhanced MR imaging of inflammatory atherosclerotic lesions: overview of experimental and initial clinical results].
Schmitz SA
Rofo; 2003 Apr; 175(4):469-76. PubMed ID: 12677500
[TBL] [Abstract][Full Text] [Related]
54. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Li J; Jameson MB; Baguley BC; Pili R; Baker SD
Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
[TBL] [Abstract][Full Text] [Related]
55. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
McKeage MJ; Fong P; Jeffery M; Baguley BC; Kestell P; Ravic M; Jameson MB
Clin Cancer Res; 2006 Mar; 12(6):1776-84. PubMed ID: 16551862
[TBL] [Abstract][Full Text] [Related]
56. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Browne WL; Wilson WR; Baguley BC; Ching LM
Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
[TBL] [Abstract][Full Text] [Related]
57. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
58. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI.
Leenders W; Küsters B; Pikkemaat J; Wesseling P; Ruiter D; Heerschap A; Barentsz J; de Waal RM
Int J Cancer; 2003 Jul; 105(4):437-43. PubMed ID: 12712432
[TBL] [Abstract][Full Text] [Related]
59. Abdominal MR angiography performed using blood pool contrast agents: comparison of a new superparamagnetic iron oxide nanoparticle and a linear gadolinium polymer.
Nolte-Ernsting C; Adam G; Bücker A; Berges S; Bjørnerud A; Günther RW
AJR Am J Roentgenol; 1998 Jul; 171(1):107-13. PubMed ID: 9648772
[TBL] [Abstract][Full Text] [Related]
60. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H
Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
